Stockscreener 앱 받기
14.01
7.44%
0.9761
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead Pharmaceuticals (ARWR) Q2 Earnings Set for May 12 Rele - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Q2 Earnings Set for May 12 Release - GuruFocus
Trend Tracker for (ARWR) - news.stocktradersdaily.com
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences - BioSpace
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences | ARWR Stock News - GuruFocus
Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt? - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results - BioSpace
Learn to Evaluate (ARWR) using the Charts - news.stocktradersdaily.com
Arrowhead CFO Ken Myszkowski to retire, Daniel Apel to succeed - MSN
Arrowhead appoints new CFO as Myszkowski retires By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer - BioSpace
Arrowhead (ARWR) Announces CFO Transition as Ken Myszkowski Reti - GuruFocus
Arrowhead Pharmaceuticals Names Daniel Apel Chief Financial Officer - marketscreener.com
Long Term Trading Analysis for (ARWR) - news.stocktradersdaily.com
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,533,337, According to a Recent SEC Filing - marketscreener.com
Arrowhead Pharmaceuticals CEO sells $1.53 million in stock By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals CEO sells $1.53 million in stock - Investing.com Australia
Arrowhead Pharmaceuticals CEO Sells Over $1.5 Million in Company Stock - TradingView
ARROWHEAD RESEARCH : Increases Ownership in Ablaris to 64% - MarketScreener
Insiders Could Have Profited By Holding onto Arrowhead Pharmaceuticals Shares Despite 23% Drop - simplywall.st
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Arrowhead stock hits 52-week low at $11.92 amid market challenges - Investing.com Canada
Rnai Technology Market Generated Opportunities, Future Scope - openPR.com
Rnai Technology Market Set to Witness Significant Growth - openPR
Arrowhead stock hits 52-week low at $14.21 amid market challenges - Investing.com Canada
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance
Arrowhead Pharmaceuticals Is Finally Arriving (NASDAQ:ARWR) - Seeking Alpha
Arrowhead shareholders approve board, executive pay - Investing.com
(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
RNA Therapies Clinical Trials and Pipeline 2025: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight - The Globe and Mail
First Capital REIT Announces March 2025 Distribution - The Globe and Mail
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by US Bancorp DE - Defense World
Bank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL.com
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - Simply Wall St
Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements - TipRanks
Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks
Mutual of America Capital Management LLC Sells 1,519 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - BioSpace
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients - Marketscreener.com
Arrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3 - Nasdaq
Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy - Marketscreener.com
Arrowhead Clinical Trial: 87% C3 Reduction in IgA Nephropathy Patients - StockTitan
Arrowhead Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Pharma Pulse 3/7/25: Overcoming Health Data Blockages in Polypharmacy, How Insurers Responded to Disasters & more - Pharmaceutical Executive
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Lelezard
Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment - Marketscreener.com
Arrowhead advances RNAi obesity treatments in clinical trials - Investing.com
Arrowhead advances RNAi obesity treatments in clinical trials By Investing.com - Investing.com UK
0.81%
자본화:
|
볼륨(24시간):